
Novartis India Launches Pluvicto, Bringing Advanced Precision Therapy for Prostate Cancer Patients
June 18, 2026
Novartis India has announced the launch of Pluvicto, India’s first regulatory-approved radioligand therapy designed for eligible patients suffering from PSMA-positive metastatic prostate cancer, marking a significant advancement in precision oncology treatment in the country. The newly introduced therapy, Pluvicto (lutetium-177Lu









